Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

1.3650

-0.0050

(-0.36%)

As of 01:58PM EDT. Market open.

Loading interactive chart…

GuruFocus.com
Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery
Explore key insights from Veru Inc's Q2 2024 earnings, emphasizing improved financial management and strategic advancements in pharmaceutical development.
GuruFocus.com
Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains
Veru's Innovative Clinical Programs Progress as Financial Challenges Persist
GlobeNewswire
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise-- --Company to present this month at upcoming American Association of Clinical Endocrinology annual meeting and GLP-1 Based Therapeutics Summit-- --Company to host conference call and webcast today at 8:00